Study guide

21.1 Initiation Training and Readiness Walkthroughs

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

21.1 Initiation Training and Readiness Walkthroughs

Key Takeaways Explain This Topic AI

Training should prepare affected people before they perform the task.

PI attendance throughout one meeting is not a universal ICH format requirement.

A practical walkthrough can expose access, handoff and supply gaps despite complete certificates.

Last updated: October 2026

Initiation Training and Readiness Walkthroughs

A rigorous SIV follows a structured, multi-hour instructional agenda:

Protocol In-Depth Review & Scientific Objectives:

Study background, preclinical rationale, and primary/secondary endpoints.

Detailed walkthrough of inclusion and exclusion criteria to prevent screen failures and accidental enrollment of ineligible participants.

Visit schedule and flow: specific testing windows (e.g., Day 14 ± 2 days 14 \pm 2\text{ days} 14 ± 2 days ), protocol-mandated fasting, and order of clinical assessments (e.g., patient-reported outcomes before invasive blood draws).

Safety Surveillance & Serious Adverse Event (SAE) Reporting:

Differentiating Adverse Events (AEs), Adverse Drug Reactions (ADRs), and Serious Adverse Events (SAEs).

The non-negotiable protocol-defined immediate reporting process : the site must report any SAE to the sponsor within the trial-specific deadline of first awareness, regardless of perceived causality or relationship to the investigational product.

Emergency unblinding procedures: locating emergency unblinding codes in the IRT system and protocol rules for code breaking.

Investigational Product Management & Accountability:

Unblinded pharmacy procedures: reconstitution, dilution, and kit numbering.

Storage requirements, continuous temperature logging, and excursion response workflows.

Maintenance of Master Drug Accountability Logs (DAL) and Subject Dispensing Logs.

Biological Sample Collection, Processing & Logistics:

Laboratory kit inventories, the actual laboratory manual and required processing instructions.

protocol-specified specimen conditions, storage labeling, and chain-of-custody logs.

Appropriate packaging, trained handling and shipment under applicable requirements for the actual materials.

Electronic Data Capture (EDC) & Data Integrity Standards:

Training staff on eCRF completion guidelines, ALCOA+ principles, and source documentation standards.

Sponsor expectations for data entry turnaround times (under the trial's data-entry requirements).

Electronic query resolution processes and investigator electronic signature requirements.

Investigator Site File (ISF) Organization & Delegation of Authority:

Inspecting the regulatory binder to ensure all essential documents are filed contemporaneously.

Finalizing the Delegation of Authority (DOA) Log : ensuring that tasks delegated by the PI align with staff qualifications, licenses, and specific protocol training.

Post-SIV Activities, Action Item Tracking & The Path to First Patient Screened

Conducting the SIV meeting does not automatically authorize the site to begin patient enrollment. Several post-visit administrative gates must be cleared:

SIV Monitoring Report and Follow-Up Letter

Within the timelines in the applicable sponsor procedures:

SIV Report: The CRA drafts a detailed, auditable monitoring report documenting the date, location, attendees, topics trained, facility re-inspection findings, and outstanding action items. The report undergoes review and sign-off by the Clinical Project Manager.

SIV Follow-Up Letter: The CRA issues a formal follow-up letter addressed to the Principal Investigator. The letter outlines all agreed-upon action items, specifies the responsible individual for each item, and assigns strict target completion dates.

Common Post-SIV Action Items

Start-up frequently requires resolving minor operational bottlenecks post-SIV:

Obtaining missing system credentials for EDC, IRT, or central laboratory portals.

Completing protocol-specific training for a secondary sub-investigator or weekend coordinator who could not attend the general SIV.

Finalizing the calibration certification for a newly installed pharmacy backup data logger.

Obtaining signed and dated normal reference ranges for a newly selected local backup laboratory.

Activity-specific authorisation and first screening

Once the required readiness conditions are verified, the sponsor issues the formal written Regulatory Green Light . The site is activated in the IRT system, investigational drug supplies are released for dispensing, and the clinical research team is officially authorized to begin pre-screening patient databases, consenting candidates, and screening the trial's first subject.

Verifying readiness through a practical walkthrough

Before release for the relevant activity, ask staff to describe a participant's first planned visit from contact through data entry. Identify which approved information is used, who checks eligibility, how a critical result reaches the investigator, where product is obtained and what happens if a system is unavailable. A walkthrough can expose an interface gap that a document checklist misses.

For example, staff may all have training certificates while no one has active access to the laboratory portal. If the first dose depends on a laboratory result, that access gap matters clinically. Resolve the dependent readiness issue and retain evidence. A low-impact filing action can sometimes remain open under an authorised plan, while a critical access or safety gap cannot be dismissed as paperwork.

Record what the site is authorised to do and what remains restricted. A participant-screening permission is not necessarily permission to dose, and a successful staff meeting is not authority approval. The sponsor's process should make these distinctions clear enough that the site can follow them without guessing.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .